AMA Update

Latest Episodes:

New CDC guidelines and tracking COVID-19 risk in your area with Andrea Garcia, JD, MPH Mar 02, 2022

Show notes

AMA CXO Todd Unger reviews COVID-19 case numbers and trending topics related to the pandemic over the past week with AMA Director of Science, Medicine and Public Health Andrea Garcia. Also covering new data from CDC studies, understanding community risk and finding your local COVID-19 Community Level, as well as positive long-lasting effects of COVID booster shots. Access the Centers for Disease Control and Prevention's "COVID-19 by County" tracker here: https://www.cdc.gov/coronavirus/2019-ncov/your-health/covid-by-county.html

Andrea Garcia, JD, MPH, outlines data supporting vaccinated pregnant mothers pass on COVID protection Feb 23, 2022

Show notes

AMA CXO Todd Unger reviews COVID-19 vaccine numbers and trending topics related to the pandemic over the past week with AMA Director of Science, Medicine and Public Health Andrea Garcia. Also covering the latest on coronavirus treatments, including Merk's COVID pill, as well as research outlining the positive effects of getting vaccinated during pregnancy.

The FDA on Molnupiravir and COVID-19: What physicians need to know, Part III Feb 18, 2022

Show notes

In part three of this three-part series, Aimee Hodowanec, MD, senior medical officer, Division of Antivirals, Office of Infectious Disease in the Center for Drug Evaluation and Research’s Office of New Drugs, FDA, discusses what physicians need to know about Molnupiravir as treatment for COVID-19.

Andrea Garcia, JD, MPH, discusses the latest on vaccines for children 5 and younger Feb 16, 2022

Show notes

AMA CXO Todd Unger reviews COVID-19 vaccine numbers and trending topics related to the pandemic over the past week with AMA Director of Science, Medicine and Public Health Andrea Garcia. Also covering the FDA's pivot to wait for more data on vaccines for kids under 5, and what new data from the CDC tells us about booster shots.

The FDA on Paxlovid and COVID-19: What physicians need to know, Part II Feb 15, 2022

Show notes

In part two of this three-part series, Stephanie Troy, MD, senior medical officer, Division of Antivirals, Office of Infectious Disease in the Center for Drug Evaluation and Research’s Office of New Drugs, FDA, discusses what to know about Paxlovid as treatment for COVID-19.

Sandra Fryhofer, MD, on what new FDA licensing & authorization requests mean for patients Feb 14, 2022

Show notes

AMA CXO Todd Unger dives into new developments from ACIP's emergency meeting on Feb. 4 with Dr. Sandra Fryhofer, AMA’s liaison to the Advisory Committee on Immunization Practices (ACIP), and a member of ACIP’s COVID-19 Vaccine Workgroup.

The FDA on Monoclonal Antibody Therapeutics: What physicians need to know, Part I Feb 11, 2022

Show notes

AMA president Gerald Harmon, MD, welcomes experts from the U.S. Food and Drug Administration (FDA) to discuss what prescribers need to know about COVID-19 therapeutic drugs, Paxlovid and Molnupiravir. Alternative treatment options for high-risk outpatients with mild-moderate COVID-19 are also discussed. Guest: John Farley, MD, MPH, director, Office of Infectious Diseases in the Center for Drug Evaluation and Research’s Office of New Drugs, FDA

Andrea Garcia, JD, MPH, shares new CDC data on detecting COVID surges in advance Feb 09, 2022

Show notes

Gerald Harmon, MD, on what physicians need to know about COVID-19 therapeutics Feb 07, 2022

Show notes

AMA CXO Todd Unger is joined by the AMA’s president, Gerald Harmon, MD, a family medicine specialist in Pawleys Island, S.C., who shares new information and big takeaways about therapeutics for COVID-19 after his recent conversation with three physician leaders from the FDA.

David Rubin, MD, on keeping kids in school in the wake of Omicron Feb 03, 2022

Show notes

AMA CXO Todd Unger talks with David Rubin, MD, director of PolicyLab at Children’s Hospital of Philadelphia and a professor of pediatrics at the Perelman School of Medicine at the University of Pennsylvania, about his team's nationally recognized COVID-19 forecasting model and how it informs new guidance for K-12 educational settings aimed at keeping kids in school.

Our TOPPODCAST Picks

Follow Us

Stay Connected

Related Podcasts

Links

Stay Connected